{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:05Z","timestamp":1788243365187,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Eisai Co., Ltd."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Perampanel is an approved adjunctive treatment for focal seizures with or without focal to bilateral tonic\u2010clonic (<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>) seizures and generalized tonic\u2010clonic (<jats:styled-content style=\"fixed-case\">GTC<\/jats:styled-content>) seizures. We compared efficacy and safety of perampanel vs placebo in Asian and non\u2010Asian populations in a post hoc analysis of pooled data from 5 randomized phase 3 studies. Patients (\u226512\u00a0years old) with focal\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>seizures received perampanel 2, 4, 8, or 12\u00a0mg or placebo; patients with<jats:styled-content style=\"fixed-case\">GTC<\/jats:styled-content>seizures received perampanel 8\u00a0mg or placebo (titration: 4\u20106\u00a0weeks; maintenance: 13\u00a0weeks). Efficacy endpoints included median percentage change in<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>or<jats:styled-content style=\"fixed-case\">GTC<\/jats:styled-content>seizure frequency per 28\u00a0days and 50% responder rate relative to baseline. Median percentage change in<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>seizure frequency was significantly greater for perampanel 8 and 12\u00a0mg than placebo in the Asian population (median difference from placebo: \u221230.32%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0017; \u221230.06%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0008, respectively) and perampanel 4, 8, and 12\u00a0mg in the non\u2010Asian population (\u221235.07%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0001; \u221237.78%,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001; \u221234.53%,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001, respectively). In both populations, median percentage change in<jats:styled-content style=\"fixed-case\">GTC<\/jats:styled-content>seizure frequency was significantly greater for perampanel 8\u00a0mg than placebo (median difference from placebo: Asian, \u221237.37%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0139; non\u2010Asian, \u221227.04%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0006). The 50% responder rates were significantly greater than placebo for perampanel 8 and 12\u00a0mg for<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>seizures (Asian: 58.0%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0017 and 58.6%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0013, respectively; non\u2010Asian: 59.3%,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001 and 54.3%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0050, respectively) and perampanel 8 mg for<jats:styled-content style=\"fixed-case\">GTC<\/jats:styled-content>seizures (Asian: 57.6%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0209; non\u2010Asian: 68.8%,<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0329). Pooled<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">GTC<\/jats:styled-content>seizure data showed generally similar patterns of response to perampanel in both populations. The most frequent treatment\u2010related adverse events were fatigue, irritability, dizziness, somnolence, and headache. Perampanel was effective, well tolerated, and can be considered a therapeutic option for<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">GTC<\/jats:styled-content>seizures in Asian populations.<\/jats:p>","DOI":"10.1111\/epi.14644","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T10:00:13Z","timestamp":1552557613000},"page":"47-59","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of perampanel in generalized and focal to bilateral tonic\u2010clonic seizures: A comparative study of Asian and non\u2010Asian populations"],"prefix":"10.1111","volume":"60","author":[{"given":"Takuji","family":"Nishida","sequence":"first","affiliation":[{"name":"National Epilepsy Center Shizuoka Institute of Epilepsy and Neurological Disorders, National Hospital Organization Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology Seoul National University College of Medicine, Seoul National University Hospital Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology Chang Gung Memorial Hospital and University Taoyuan City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somsak","family":"Tiamkao","sequence":"additional","affiliation":[{"name":"Department of Medicine Faculty of Medicine, Integrated Epilepsy Research Group Khon Kaen University Khon Kaen Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-4021","authenticated-orcid":false,"given":"Amitabh","family":"Dash","sequence":"additional","affiliation":[{"name":"Eisai Singapore Pte. Ltd. Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Food and Drug Administration.Fycompa\u00aeprescribing information September 2018. Available at:https:\/\/www.fycompa.com\/-\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf. Accessed October 3 2018."},{"key":"e_1_2_9_3_1","unstructured":"European Medicines Agency.Fycompa\u00aeannex I: summary of product characteristics. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002434\/WC500130815.pdf. Accessed August 30 2018."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.2743"},{"key":"e_1_2_9_5_1","unstructured":"Food and Drug Administration.Dilantin\u00aelabel. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/010151s036lbl.pdf. Accessed August 30 2018."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.2.192"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.33903.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01075.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02952.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2009.01932.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.4.462"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911610"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60176-1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.70"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.05.031"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.9.2.291"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.15801.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000142991.14507.B5"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.80092"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.128544"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721090-00005"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.823399"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12883"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001930"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2017.01.014"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01716.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7859"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000211"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12874"},{"key":"e_1_2_9_33_1","unstructured":"ICH.Introductory guide for Standardised MedDRA Queries (SMQs) version 16.0.2013. Available at:https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_16_0_english.pdf. Accessed August 30 2018."},{"issue":"14","key":"e_1_2_9_34_1","doi-asserted-by":"crossref","first-page":"P1.254","DOI":"10.1212\/WNL.84.14_supplement.P1.254","article-title":"Subgroup analysis by race in perampanel phase III clinical studies","volume":"84","author":"Laurenza A","year":"2015","journal-title":"Neurology"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S2158"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1195810"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01022.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001558"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002700"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12116"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6526-2"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00279.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.14644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.14644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T20:01:36Z","timestamp":1721073696000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.14644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":41,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/epi.14644"],"URL":"https:\/\/doi.org\/10.1111\/epi.14644","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2017-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}